Matthew L. Posard insider trades
Open-market stock purchases and sales by Matthew L. Posard, Director at Halozyme Therapeutics, Inc, from SEC Form 4 filings since Mar 8, 2012.
Track record: 0% of 2 scored buys are up 5% or more since purchase, averaging -47%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Sep 16, 2026 | HALO Halozyme Therapeutics, Inc | Sold | $329K |
| Sep 16, 2026 | HALO Halozyme Therapeutics, Inc | Sold | $320K |
| Sep 16, 2026 | HALO Halozyme Therapeutics, Inc | Sold | $961K |
| Sep 16, 2026 | HALO Halozyme Therapeutics, Inc | Sold | $436K |
| Jun 18, 2026 | NAUT Nautilus Biotechnology, Inc | Bought (not open market) | — |
| May 5, 2026 | HALO Halozyme Therapeutics, Inc | Bought (not open market) | — |
| May 5, 2026 | HALO Halozyme Therapeutics, Inc | Bought (not open market) | — |
Companies traded
- HALO Halozyme Therapeutics, Inc: 12 sales, last Sep 16, 2026
- NAUT Nautilus Biotechnology, Inc: 2 buys, last Jun 18, 2026
- TLIS Talis Biomedical Corp: 1 buy, last Jun 9, 2023
- DMTK DermTech, Inc: 1 buy, last Jun 1, 2023
- TROV Trovagene, Inc: other filings, last Jan 4, 2016
- ILMN Illumina Inc: 9 sales, last May 30, 2013